Patent ID: 9555058
Date: 2017-01-31
CPC Classifications: A61K,A61P

Claim:
1. A melanoma vaccine comprising: a population of melanoma cells comprising melanoma peptides from a subject with melanoma, contacted, in vitro, with an antigen presenting cell (APC) from the same subject, wherein the population of melanoma cells (a) is selected for being at least 60% autophagic, non-apoptotic, and MHC class II expressing, by one or more of flow cytometry, affinity chromatography, immunomagnetic separation, or adherence to a tissue culture surface; (b) is not treated with IFN-gamma; (c) is metabolically active; (d) is treated, in vitro, with an inhibitor of apoptosis, and wherein the contact between the melanoma cells and the APCs results in APCs comprising the melanoma peptides that are partially or substantially processed.